CTXR · Citius Pharmaceuticals, Inc. · Shareholders & Ownership

Substantial doubt about the company's ability to continue as a going concern.

“The Company estimates that its and Citius Oncology's collective available cash resources will be sufficient to fund our operations through November 2026. We will need to raise additional capital in the future to support our operations beyond November 2026, which raises substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued.”